Search

Your search keyword '"Einarsson R"' showing total 336 results
Start Over Author "Einarsson R"
336 results on '"Einarsson R"'

2. Nomograms including the UBC (R) Rapid test to detect primary bladder cancer based on a multicentre dataset

Author

Meisl, CJ, Karakiewicz, PI, Einarsson, R, Koch, S, Hallmann, S, Weiss, S, Hemdan, T, Malmstrom, PU, Styrke, J, Sherif, A, Hasan, MN, Pichler, R, Tulchiner, G, Palou, J, Faba, OR, Hennenlotter, J, Stenzl, A, Ritter, R, Niegisch, G, Grunewald, CM, Schlomm, T, Friedersdorff, F, Barski, D, Otto, T, Gossl, A, Arndt, C, Esuvaranathan, K, Kesavan, NR, Zang, ZJ, Kramer, MW, Hennig, MJP, and Ecke, TH

Subjects
nomogram, #uroonc, #blcsm, urothelial cancer, diagnosis, UBC (R) Rapid test, #BladderCancer, bladder cancer, logistic model
Abstract

Objectives To evaluate the clinical utility of the urinary bladder cancer antigen test UBC (R) Rapid for the diagnosis of bladder cancer (BC) and to develop and validate nomograms to identify patients at high risk of primary BC. Patients and Methods Data from 1787 patients from 13 participating centres, who were tested between 2012 and 2020, including 763 patients with BC, were analysed. Urine samples were analysed with the UBC (R) Rapid test. The nomograms were developed using data from 320 patients and externally validated using data from 274 patients. The diagnostic accuracy of the UBC (R) Rapid test was evaluated using receiver-operating characteristic curve analysis. Brier scores and calibration curves were chosen for the validation. Biopsy-proven BC was predicted using multivariate logistic regression. Results The sensitivity, specificity, and area under the curve for the UBC (R) Rapid test were 46.4%, 75.5% and 0.61 (95% confidence interval [CI] 0.58-0.64) for low-grade (LG) BC, and 70.5%, 75.5% and 0.73 (95% CI 0.70-0.76) for high-grade (HG) BC, respectively. Age, UBC (R) Rapid test results, smoking status and haematuria were identified as independent predictors of primary BC. After external validation, nomograms based on these predictors resulted in areas under the curve of 0.79 (95% CI 0.72-0.87) and 0.95 (95% CI: 0.92-0.98) for predicting LG-BC and HG-BC, respectively, showing excellent calibration associated with a higher net benefit than the UBC (R) Rapid test alone for low and medium risk levels in decision curve analysis. The R Shiny app allows the results to be explored interactively and can be accessed at www.blucab-index. net. Conclusion The UBC (R) Rapid test alone has limited clinical utility for predicting the presence of BC. However, its combined use with BC risk factors including age, smoking status and haematuria provides a fast, highly accurate and non-invasive tool for screening patients for primary LG-BC and especially primary HG-BC.

Published
2022

3. Entwicklung von Nomogrammen anhand des UBC®-Rapid-Tests und klinischen Parametern zur Erstdiagnose von Harnblasenkarzinomen

Author

Meisl, C., Karakiewicz, P., Einarsson, R., Koch, S., Hallmann, S., Weiß, S., Barski, D., Otto, T., Gössl, A., Arndt, C., Kramer, M., Hennig, M., and Ecke, T.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Der UBC®-Rapid-Test ist ein quantitativer Schnelltest, der Blasenkrebs (BK) durch Messung der Zytokeratinfragmente 8 und 18 im Urin nachweisen kann. Mit einer Sensitivität von 56–71% und eine Spezifität von 61–96% wird der UBC®-Rapid-Test noch [zum vollständigen Text gelangen Sie über die oben angegebene URL], 61. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.

Published
2021
Full Text
View/download PDF

11. Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up

Author

Dalen, A., Favier, J., Hallensleben, E., Burges, A., Stieber, P., Bruijn, H. W. A., Fink, D., Annamaria Ferrero, Mcging, P., Harlozinska, A., Kainz, Ch, Markowska, J., Molina, R., Sturgeon, C., Bowman, A., Einarsson, R., Goike, H., University of Zurich, and van Dalen, A

Subjects
PREDICTOR, endocrine system diseases, Survival, CARCINOMA, 610 Medicine & health, 2729 Obstetrics and Gynecology, TPS, Prognosis, TUMOR-MARKERS, THERAPY, 10174 Clinic for Gynecology, female genital diseases and pregnancy complications, Ovarian cancer, CA 125, PROGNOSTIC-SIGNIFICANCE, INDUCTION CHEMOTHERAPY, CRITERIA, 2730 Oncology, POLYPEPTIDE-SPECIFIC-ANTIGEN, CA-125 HALF-LIFE
Abstract

Purpose of investigation: To evaluate the prognostic significance for overall survival rate for the marker combination TPS and CA125 in ovarian cancer patients after three chemotherapy courses during long-term clinical follow-up. Methods: The overall survival of 212 (out of 213) ovarian cancer patients (FIGO Stages I-IV) was analyzed in a prospective multicenter study during a 10-year clinical follow-up by univariate and multivariate analysis. Results: In patients with ovarian cancer FIGO Stage 1 (34 patients) or FIGO Stage 11 (30 patients) disease, the univariate and multivariate analysis of the 10-year overall survival data showed that CA125 and TPS serum levels were not independent prognostic factors. In the FIGO Stage III group (112 patients), the 10-year overall survival was 15.2%; while in the FIGO Stage IV group (36 patients) a 10-year overall survival of 5.6% was seen. Here, the tumor markers CA125 and TPS levels were significant prognostic factors in both univariate and multivariate analysis (p

Published
2009

12. TPS - A cytokeratin marker for therapy control in breast cancer

Author

Einarsson R

Subjects
CA15-3, Oncology, medicine.medical_specialty, Time Factors, Tissue Polypeptide Antigen, Clinical Biochemistry, CA 15-3, Breast Neoplasms, Epitope, Epitopes, Cytokeratin, Text mining, Breast cancer, Internal medicine, Keratin, Biomarkers, Tumor, medicine, Humans, chemistry.chemical_classification, business.industry, General Medicine, medicine.disease, chemistry, Cancer research, Keratins, Female, Peptides, business
Published
1995

13. An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer

Author

Byström, P., Berglund, Åke, Nygren, Peter, Wernroth, Mona-Lisa, Johansson, Birgitta, Larsson, Anders, Einarsson, R., Glimelius, Bengt, Byström, P., Berglund, Åke, Nygren, Peter, Wernroth, Mona-Lisa, Johansson, Birgitta, Larsson, Anders, Einarsson, R., and Glimelius, Bengt

Abstract

The value of early tumour marker changes during palliative chemotherapy in patients with upper gastrointestinal adenocarcinoma (UGIA) is unclear. Seventy-three patients with advanced UGIA were randomised to receive 45 mg/m2 docetaxel or 180 mg/m2 irinotecan with 5-FU/leucovorin. After every 2nd course the patients were crossed over to the other regimen. Serum was sampled before start of chemotherapy and every 2nd week during 8 weeks for CEA, TPA, TPS, CA72-4, CA19-9 and CA242 measurements. Eighteen patients (25%) had partial response (PR) and 21 patients had stable disease for at least 4 months (SD4). All baseline marker levels, except CA72-4, correlated with time to progression and survival. Patients with normal levels, except CA72-4, also had more clinical responses (PR+SD4) than patients with elevated values. Tumour marker changes early during treatment provided modest predictive information for tumour response and survival. A model combining baseline level, the change and the interaction between them gave the best prediction of outcome, however, insignificantly better than baseline level for all markers except CA242. Baseline tumour marker levels provide prognostic information for patients with UGIA on palliative chemotherapy. Early changes generally failed to provide accurate information for tumour response and survival.

Published
2010
Full Text
View/download PDF

15. Variability of airborne cat allergen, Fel d1, in a public place

Author

Munir, Abdul Kashem Mohamma, Einarsson, R, Dreborg, S, Munir, Abdul Kashem Mohamma, Einarsson, R, and Dreborg, S

Abstract

Allergen exposure is a risk to develop an IgE-mediated sensitization. The amount of allergen inhaled per unit time should be related to the amount present in the air, i.e. airborne allergen. Thus, measuring allergen levels in the air would be more relevant than measuring allergen levels in dust. Allergens are present in the air in very minute quantities and usually become airborne after disturbance. Large variation of allergen levels have been found in dust. In this study, we measured variability of airborne cat allergen, Fel d1, in a public place using a high-volume air-sampler. We also studied the distribution and relationship between dust and airborne cat allergens in homes and schools. Air samples were collected at three different airflow rates, i.e. 55, 40, and 30 m3 of air per hour. The concentration of airborne Fel d1 in the community gymnastic hall varied from 1 to 10 pg/m3 within a period of 3 weeks, at airflow rates 55-30 m3/h. The coefficient of variation for repeated samplings was 14-43% (day-to-day variation) and 27-38% (within-day variation). As expected, higher levels of airborne cat allergens were found in homes with cats than in cat-free environments. There was a significant relationship between cat allergen levels in dust and air (r = 0.7, P < 0.01). Our study demonstrates that when measuring airborne cat allergen a large variation is observed within a day and between days. The large variability of measurement may be explained by the disturbance in the environments. We suggest, that when exposure assessment is made the environment in question should be analyzed, if possible in several occasions.

Published
2003
Full Text
View/download PDF

18. Immunohistochemical characterization of 30 monoclonal antibodies against cytokeratin antigens. Second report of the ISOBM TD 5-1 workshop

Author

Nap, M, Andrés, L, Bishr Omary, M C, Bellanger, L, Bodenmuller, H, Bonfrer, H, Brundell, J, Einarsson, R, Erlandsson, Ann, Johansson, A, Leca, JF, Levi, M, Meir, T, Nustad, K, Seguin, P, Sjödin, A, Stigbrand, T, Sundström, Birgitta, van Dalen, A, Wioebelhaus, E, Wiklund, B, Ärl, Nap, M, Andrés, L, Bishr Omary, M C, Bellanger, L, Bodenmuller, H, Bonfrer, H, Brundell, J, Einarsson, R, Erlandsson, Ann, Johansson, A, Leca, JF, Levi, M, Meir, T, Nustad, K, Seguin, P, Sjödin, A, Stigbrand, T, Sundström, Birgitta, van Dalen, A, Wioebelhaus, E, Wiklund, B, and Ärl

Published
2001

21. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens. The ISOBM TD5-1 Workshop

Author

Stigbrand, T, Andrés, C, Bellanger, L, Bishr Omary, M, Bodenmüller, H, Bonfrer, H, Brundell, J, Einarsson, R, Erlandsson, Ann, Johansson, A, Leca, JF, Levi, M, Meier, T, Nap, M, Nustad, K, Seguin, P, Sjödin, A, Sundström, Birgitta, van Dahlen, A, Wiebelhaus, E, Wiklund, B, Ärlestig, L, Stigbrand, T, Andrés, C, Bellanger, L, Bishr Omary, M, Bodenmüller, H, Bonfrer, H, Brundell, J, Einarsson, R, Erlandsson, Ann, Johansson, A, Leca, JF, Levi, M, Meier, T, Nap, M, Nustad, K, Seguin, P, Sjödin, A, Sundström, Birgitta, van Dahlen, A, Wiebelhaus, E, Wiklund, B, and Ärlestig, L

Published
1998

23. Immunohistochemical Profiles of 30 Monoclonal Antibodies against Cytokeratins 8, 18 and 19

Author

Nap, M., primary, van Wel, Th., additional, Andrés, C., additional, Bellanger, L., additional, Bodenmüller, H., additional, Bonfrer, H., additional, Brundell, J., additional, Einarsson, R., additional, Erlandsson, A., additional, Johansson, A., additional, Leca, J.F., additional, Meier, T., additional, Seguin, P., additional, Sjödin, A., additional, Stigbrand, T., additional, Sundström, B.E., additional, van Dalen, A., additional, Wiebelhaus, E., additional, Wiklund, B., additional, and Hilgers, J., additional

Published
2001
Full Text
View/download PDF

24. Epitope Specificity of 30 Monoclonal Antibodies against Cytokeratin Antigens: The ISOBM TD5-1 Workshop

Author

Stigbrand (Chairman), T., primary, Andrés, C., additional, Bellanger, L., additional, Bishr Omary, M., additional, Bodenmüller, H., additional, Bonfrer, H., additional, Brundell, J., additional, Einarsson, R., additional, Erlandsson, A., additional, Johansson, A., additional, Leca, J.F., additional, Levi, M., additional, Meier, T., additional, Nap, M., additional, Nustad, K., additional, Seguin, P., additional, Sjödin, A., additional, Sundström, B., additional, van Dalen, A., additional, Wiebelhaus, E., additional, Wiklund, B., additional, Ärlestig, L., additional, and Hilgers (Coordinator), J., additional

Published
1998
Full Text
View/download PDF

28. Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes

Author

Van Dalen, A., primary, Heering, K.J., additional, Barak, V., additional, Peretz, T., additional, Cremaschi, A., additional, Geroni, P., additional, Gion, M., additional, Saracchini, S., additional, Molina, R., additional, Namer, M., additional, Stieber, P., additional, Sturgeon, C., additional, Leonard, R.C.F., additional, and Einarsson, R., additional

Published
1996
Full Text
View/download PDF

43. Hydrolysed cow's milk formulae.

Author

Businco, L., primary, Dreborg, S., additional, Einarsson, R., additional, Giampietro, P. G., additional, Hest, A., additional, Keller, K. M., additional, Strobel, S., additional, and Wahn, U., additional

Published
1993
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results